Body mass index as a driver of selection of biologic therapy in rheumatoid arthritis. Results from the US-CLARA study.

CONCLUSIONS: BMI does not influence the abatacept response in RA patients with active disease. During abatacept treatment, the clinical response can be achieved despite a condition of overweight or obesity.
PMID: 31113709 [PubMed - as supplied by publisher]

Source: European Journal of Internal Medicine - May 17, 2019 Category: Internal Medicine Authors: Di Carlo M, Salaffi F, Gremese E, Iannone F, Lapadula G, Ferraccioli G, GISEA Study Group Tags: Eur J Intern Med Source Type: research